This page is part of the FHIR Specification (v5.0.0: R5 - STU). This is the current published version in it's permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: No defined compartments |
Raw JSON (canonical form + also see JSON Format Specification)
Simple version of a product (more than basic), only using MedicinalProductDefinition, Ingredient and RegulatedAuthorization
{ "resourceType" : "MedicinalProductDefinition", "id" : "equilidem-with-ing-and-auth", "text" : { "status" : "generated", "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tGenerated Narrative\n\t\t\t\t</b>\n\t\t\t</p>\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tId\n\t\t\t\t</b>\n\t\t\t\t: equilidem-with-ing-and-auth\n\t\t\t</p>\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tIdentifier\n\t\t\t\t</b>\n\t\t\t\t: Equilidem25\n\t\t\t</p>\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tCombined Pharmaceutical Dose Form\n\t\t\t\t</b>\n\t\t\t\t:\n\t\t\t\t<span title=\"Codes: {http://example.org.uk/fhir/dosefom tablet}\">\n\t\t\t\t\ttablet\n\t\t\t\t</span>\n\t\t\t</p>\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tIndication\n\t\t\t\t</b>\n\t\t\t\t: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n\t\t\t</p>\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tLegal Status Of Supply\n\t\t\t\t</b>\n\t\t\t\t:\n\t\t\t\t<span title=\"Codes: {http://example.org.uk/fhir/legalstatusofsupply POM}\">\n\t\t\t\t\tPrescription only medicine\n\t\t\t\t</span>\n\t\t\t</p>\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tclassification\n\t\t\t\t</b>\n\t\t\t\t:\n\t\t\t\t<span title=\"Codes: {http://www.whocc.no/atc/example B01A}\">\n\t\t\t\t\tB01A\n\t\t\t\t</span>\n\t\t\t</p>\n\t\t\t<p>\n\t\t\t\t<b>\n\t\t\t\t\tIngredients\n\t\t\t\t</b>\n\t\t\t\t:\n\t\t\t</p>\n\t\t\t<blockquote>\n\t\t\t\t<p>\n\t\t\t\t\t<b>\n\t\t\t\t\t\tRole\n\t\t\t\t\t</b>\n\t\t\t\t\t:\n\t\t\t\t\t<span title=\"Codes: {http://example.org.uk/fhir/ingredientType active}\">\n\t\t\t\t\t\tactive\n\t\t\t\t\t</span>\n\t\t\t\t</p>\n\t\t\t\t<blockquote>\n\t\t\t\t\t<p>\n\t\t\t\t\t\t<b>\n\t\t\t\t\t\t\tsubstance\n\t\t\t\t\t\t</b>\n\t\t\t\t\t\t:\n\t\t\t\t\t\t<span title=\"Codes: {http://example.org.uk/fhir/substances 123456}\">\n\t\t\t\t\t\t\tEquilidonium Phosphate\n\t\t\t\t\t\t</span>\n\t\t\t\t\t</p>\n\t\t\t\t\t<table class=\"grid\">\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t-\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t<b>\n\t\t\t\t\t\t\t\t\tPresentation\n\t\t\t\t\t\t\t\t</b>\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t*\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t22 ml/1 tablet\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</table>\n\t\t\t\t</blockquote>\n\t\t\t</blockquote>\n\t\t\t<blockquote>\n\t\t\t\t<p>\n\t\t\t\t\t<b>\n\t\t\t\t\t\tRole\n\t\t\t\t\t</b>\n\t\t\t\t\t:\n\t\t\t\t\t<span title=\"Codes: {http://example.org.uk/fhir/ingredientType excipient}\">\n\t\t\t\t\t\texcipient\n\t\t\t\t\t</span>\n\t\t\t\t</p>\n\t\t\t\t<blockquote>\n\t\t\t\t\t<p>\n\t\t\t\t\t\t<b>\n\t\t\t\t\t\t\tsubstance\n\t\t\t\t\t\t</b>\n\t\t\t\t\t\t:\n\t\t\t\t\t\t<span title=\"Codes: {http://example.org.uk/fhir/substances 456789}\">\n\t\t\t\t\t\t\tCalcium Carbonate\n\t\t\t\t\t\t</span>\n\t\t\t\t\t</p>\n\t\t\t\t\t<table class=\"grid\">\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t-\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t<b>\n\t\t\t\t\t\t\t\t\tPresentation\n\t\t\t\t\t\t\t\t</b>\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t*\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t\t<td>\n\t\t\t\t\t\t\t\t3 ml/tablet\n\t\t\t\t\t\t\t</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</table>\n\t\t\t\t</blockquote>\n\t\t\t</blockquote>\n\t\t\t<h3>\n\t\t\t\tNames\n\t\t\t</h3>\n\t\t\t<table class=\"grid\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t-\n\t\t\t\t\t</td>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t<b>\n\t\t\t\t\t\t\tProductName\n\t\t\t\t\t\t</b>\n\t\t\t\t\t</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t*\n\t\t\t\t\t</td>\n\t\t\t\t\t<td>\n\t\t\t\t\t\tEquilidem 2.5 mg film-coated tablets\n\t\t\t\t\t</td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<h3>\n\t\t\t\tCross References\n\t\t\t</h3>\n\t\t\t<table class=\"grid\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t-\n\t\t\t\t\t</td>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t<b>\n\t\t\t\t\t\t\tProduct\n\t\t\t\t\t\t</b>\n\t\t\t\t\t</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t*\n\t\t\t\t\t</td>\n\t\t\t\t\t<td>\n\t\t\t\t\t\tLink to generic equivalent\n\t\t\t\t\t</td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t\t<h3>\n\t\t\t\tManufacturing Business Operations\n\t\t\t</h3>\n\t\t\t<table class=\"grid\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t-\n\t\t\t\t\t</td>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t<b>\n\t\t\t\t\t\t\tManufacturer\n\t\t\t\t\t\t</b>\n\t\t\t\t\t</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t*\n\t\t\t\t\t</td>\n\t\t\t\t\t<td>\n\t\t\t\t\t\t<span>\n\t\t\t\t\t\t\tEquiliDrugCo Processing Inc.\n\t\t\t\t\t\t</span>\n\t\t\t\t\t</td>\n\t\t\t\t</tr>\n\t\t\t</table>\n\t\t</div>" }, "contained" : [{ "resourceType" : "Ingredient", "id" : "EquilidoniumPhosphate", "status" : "active", "for" : [{ "reference" : "#" }], "role" : { "coding" : [{ "system" : "http://example.org.uk/fhir/ingredientType", "code" : "active" }] }, "substance" : { "code" : { "concept" : { "coding" : [{ "system" : "http://example.org.uk/fhir/substances", "code" : "123456", "display" : "Equilidonium Phosphate" }] } }, "strength" : [{ "presentationRatio" : { "numerator" : { "value" : 22, "unit" : "ml", "system" : "http://unitsofmeasure.org", "code" : "mL" }, "denominator" : { "value" : 1, "unit" : "tablet" } } }] } }, { "resourceType" : "Ingredient", "id" : "CalciumCarbonate", "status" : "active", "for" : [{ "reference" : "#" }], "role" : { "coding" : [{ "system" : "http://example.org.uk/fhir/ingredientType", "code" : "excipient" }] }, "substance" : { "code" : { "concept" : { "coding" : [{ "system" : "http://example.org.uk/fhir/substances", "code" : "456789", "display" : "Calcium Carbonate" }] } }, "strength" : [{ "presentationRatio" : { "numerator" : { "value" : 3, "unit" : "ml", "system" : "http://unitsofmeasure.org", "code" : "mL" }, "denominator" : { "value" : 1, "unit" : "tablet" } } }] } }], "identifier" : [{ "system" : "http://example.org.uk/fhir/product", "value" : "Equilidem25" }], "combinedPharmaceuticalDoseForm" : { "coding" : [{ "system" : "http://example.org.uk/fhir/dosefom", "code" : "tablet" }] }, "indication" : "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.", "legalStatusOfSupply" : { "coding" : [{ "system" : "http://example.org.uk/fhir/legalstatusofsupply", "code" : "POM", "display" : "Prescription only medicine" }] }, "classification" : [{ "coding" : [{ "system" : "http://www.whocc.no/atc/example", "code" : "B01A" }] }], "name" : [{ "productName" : "Equilidem 2.5 mg film-coated tablets" }], "crossReference" : [{ "product" : { "reference" : { "reference" : "MedicinalProductDefinition/genericEquilidonium" } } }], "operation" : [{ "organization" : [{ "display" : "EquiliDrugCo Processing Inc." }] }] }
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R5 hl7.fhir.core#5.0.0 generated on Sun, Mar 26, 2023 15:25+1100.
Links: Search |
Version History |
Contents |
Glossary |
QA |
Compare to R4 |
Compare to R4B |
|
Propose a change